Format

Send to

Choose Destination
Clin Infect Dis. 2020 Feb 1. pii: ciaa102. doi: 10.1093/cid/ciaa102. [Epub ahead of print]

Effectiveness of Trivalent and Quadrivalent Inactivated Vaccines against Influenza B in the United States, 2011-2012 to 2016-2017.

Author information

1
Baylor Scott & White Health, Texas A&M University College of Medicine, Temple TX.
2
Marshfield Clinic Research Institute, Marshfield WI.
3
Kaiser Permanente Washington Health Research Institute, Seattle WA.
4
University of Pittsburgh, Schools of Health Sciences, Pittsburgh PA.
5
University of Michigan School of Public Health, Ann Arbor MI.
6
Influenza Division, Centers for Disease Control and Prevention, Atlanta GA.

Abstract

BACKGROUND:

Since 2013, quadrivalent influenza vaccines containing two B viruses gradually replaced trivalent vaccines in the United States. We compared vaccine effectiveness of quadrivalent to trivalent inactivated vaccines (IIV4 to IIV3) against illness due to influenza B during the transition when IIV4 use increased rapidly.

METHODS:

The US Influenza Vaccine Effectiveness (Flu VE) Network analyzed 25,019 of 42,600 outpatients aged ≥6 months enrolled within 7 days of illness-onset during six seasons from 2011-2012. Upper respiratory specimens were tested for influenza virus type and B-lineage. Using logistic regression, we estimated IIV4 or IIV3 effectiveness by comparing the odds of influenza B infection overall, and by B lineage among vaccinated versus unvaccinated participants. Over four seasons from 2013-2014, we compared relative odds of influenza B infection among IIV4 versus IIV3 recipients.

RESULTS:

Trivalent vaccines included the predominantly circulating B lineage in four of six seasons. During four influenza seasons when both IIV4 and IIV3 were widely used, overall effectiveness against any influenza B was 53% (95% confidence interval [CI], 45 to 59) for IIV4 versus 45% (95% CI, 34 to 54) for IIV3. IIV4 was more effective than IIV3 against the B lineage not included in IIV3, but comparative effectiveness against illness related to any influenza B favored neither vaccine valency.

CONCLUSIONS:

Uptake of quadrivalent inactivated influenza vaccines was not associated with increased protection against any influenza B illness, despite higher effectiveness of quadrivalent vaccines against the added B virus lineage. Public health impact and cost-benefit analyses are needed globally.

KEYWORDS:

Inactivated influenza vaccine; Influenza B lineage; Quadrivalent; Trivalent; effectiveness

PMID:
32006430
DOI:
10.1093/cid/ciaa102

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center